BRIEF—Evotec Biologics and Alpine Immune Sciences expand partnership

Just-Evotec Biologics and Alpine Immune Sciences have announced a multi-year partnership for the development of ALPN-303, an engineered TACI domain for the treatment of systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases.

Seattle-based Just-Evotec is a subsidiary of German life science company Evotec.

The contract is a continuation of the companies' first-in-human program in which Just-Evotec delivered drug substance materials using its J.DESIGN continuous manufacturing platform for Alpine’s ongoing Phase I study and anticipated Phase II studies of ALPN-303.

Just-Evotec will leverage its data-driven technology platform to develop a commercial manufacturing process for ALPN-303. The program includes upstream and downstream process, analytical method, and formulation development with a view to supporting commercial manufacturing of ALPN-303.